INTRODUCTION {#S1}
============

Recurrent depressive disorder is a common psychiatric disorder associated with high morbidity, high economic burden and high rates of completed suicide ([@R1]-[@R3]). Depressive disorder is heritable, with recurrent and severe types being substantially so ([@R4], [@R5]), but the specific genes involved are not known. Since recurrent depression is associated with increased mortality at a young age ([@R3]) it is logical to expect that some of the genetic contribution to the disorder may be explained by rare genomic variants operating under negative selection pressure ([@R6]).

Genome-wide association studies of single nucleotide polymorphisms have been inconsistent in depression ([@R7], [@R8]). However there is increasingly robust evidence that copy number variants (CNV), defined as submicroscopic deletions or duplications of genomic DNA seen at a frequency of less than 1 in 100 in the general population ([@R9]), are associated with a range of psychiatric disorders ([@R10]-[@R16]). A genome wide analysis of CNVs in recurrent depression has not yet been undertaken. Thus we decided to analyse Illumina microarray data for evidence of copy number variation in a large cohort of cases of recurrent depression and compare this to two control samples; one consisting of participants screened for a lifetime-absence of psychiatric disorder and another larger, unscreened population control cohort from phase 2 of the Wellcome Trust Case Control Consortium (WTCCC2).

METHODS {#S2}
=======

SAMPLES {#S3}
-------

3,106 cases (2,188 female & 918 male) of depression were taken from two studies of recurrent depression and a pharmacogenetic study of antidepressant response. Details of these studies have been published elsewhere ([@R17]-[@R19]) and further details are also provided in the [supplementary information](#SD1){ref-type="supplementary-material"}. All studies were approved by local ethics committees and informed written consent was gained from all participants. All cases were ascertained by interview with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) ([@R20]) and fulfilled criteria for depression of at least moderate severity (2 or more episodes) under ICD-10 or DSM IV criteria. Subjects were excluded if there was a history or family history of schizophrenia or bipolar disorder or if mood symptoms were secondary to alcohol or substance misuse. Subjects with mood congruent psychotic symptoms were not excluded.

459 controls (281 female & 178 male) comprehensively screened for a lifetime-absence of psychiatric disorder were recruited. Potential subjects for the screened control group were collected from students and staff at Kings College London by internal email advertisement and by local media advertisement. Subjects were interviewed with a modified version of the Past History Schedule ([@R21]) and were included only if they demonstrated no evidence of past or present psychiatric disorder. Subjects were also interviewed with the Beck Depression Inventory ([@R22]) and excluded if they scored more than 10.

As an additional control set we also used 5,619 control samples (2,611 female & 2,668 male) from phase 2 of the Wellcome Trust Case Control Consortium (WTCCC2) composed of the 1958 British birth cohort and the national blood service cohort. The 1958 British birth cohort is a sample of sequential live births in the UK during one week in 1958, whilst the national blood service cohort is drawn from subjects who have donated blood to the UK blood services collection (further details can be found in the [supplementary information](#SD1){ref-type="supplementary-material"}).

Our control samples are of exclusively UK ethnic origin. However some of our case samples have non-UK, European heritage. Within our analyses we have attempted to account for this potential confounding factor by performing an additional analysis restricted to samples with exclusively UK origins.

GENOTYPING {#S4}
----------

All DNA samples were obtained from venous blood. We genotyped our case sample and screened control samples on the Illumina (San Diego, CA, USA) HumanHap 610-Quad Beadchip and all DNA samples were processed contemporaneously at the same laboratory with stringent quality control and full Laboratory Information Management Systems (LIMS) monitoring. Samples from the WTCCC2 cohort were genotyped on a modified Illumina 1M beadchip which is technically very similar to the 610-Quad beadchip. We were granted access to the chip intensity data (Illumina '.idat' files). All probe intensity data was normalised and processed using standard Illumina protocols with Illumina's GenomeStudio platform to obtain the log R ratio (LRR) and B allele frequency (BAF) at each marker. The LRR and BAF represent, for each marker in each sample, a summed probe intensity ratio derived from comparison to a canonical value calculated from all samples, and, in the case of bi-allelic probes, an allelic intensity ratio, respectively.

CNV CALLING {#S5}
-----------

All our calls and analysis are based on build 18 of the human genome reference sequence. We processed LRR and BAF values for autosomal markers in common to both Illumina arrays (n=562,680) using PennCNV (version released August 2009), a popular, open-source package designed for Illumina array data that implements a hidden Markov model, a Viterbi algorithm, expectation maximisation and takes account of the distance between consecutive markers to make copy number calls ([@R23]).

SAMPLE AND CNV QUALITY CONTROL {#S6}
------------------------------

Samples with a genotype call rate of less than 98%, a B allele frequency standard deviation (BAFSD) of more than 0.045 or a log R ratio standard deviation (LRRSD) of more than 0.3 were excluded from analysis. We excluded all CNVs of less than 100kb and all CNVs made with less than 10 consecutive markers. We excluded samples with more than a total of 20 CNVs, as such samples are more likely to contain artefactual calls. We excluded calls that fell within 500kb of the centromere or telomere of each chromosome and any calls falling within immunoglobulin regions. We excluded calls occurring in more than 1% of our control sample, and calls made over regions of the genome where the marker density was low (\<1 marker per 200,000bp (n=134)).

As an additional level of assurance that our results were not biased by poorly performing samples clustering in particular cohorts, we removed the worst performing 10% of samples as defined by the LRRSD and BAFSD across all cohorts and re-analysed our data. This tightened our thresholds for inclusion of a sample in this analysis to a LRRSD of 0.2241, a BAFSD of 0.0390 and a genotype call rate of greater than 99%.

STATISTICAL ANALYSIS {#S7}
--------------------

To test for statistical significance and effect sizes we calculated odds ratios, Pearson's chi-square or Fisher's exact statistic for the frequency of samples with CNVs in cases and controls. We estimated the proportion of genetic risk for depression contributed to by our results by performing a logistic regression analysis and calculating pseudo R^2^. All statistical calculations were performed in STATA IC v10.1 ([@R24]) or PLINK v1.07 ([@R25]). Graphs were created using STATA IC v10.1 and Microsoft Excel (2011).

Further information on methods and analysis can be found in the [supplementary information](#SD1){ref-type="supplementary-material"}.

RESULTS {#S8}
=======

2,723 cases of recurrent depression, 348 screened controls and 4,828 unscreened controls passed quality control and were used in our main analysis. Overall, the proportion of samples with a CNV was increased in cases when compared to screened controls and WTCCC2 controls (p=0.019, OR=1.31 (95% CI 1.04 - 1.64) and p=0.025, OR=1.11 (95% CI 1.01 - 1.23) respectively). After stratifying by type of CNV, deletions accounted for this change in both cohorts (p=5.6×10^−4^, OR=1.52 (95% CI 1.20 - 1.93) and p=7.7×10^−6^, OR =1.25 (95% CI 1.13 - 1.37) respectively). [Table 1](#T1){ref-type="table"} illustrates the frequency of samples with a CNV, stratified into deletions and duplications, in screened controls, WTCCC2 controls, and cases. [Fig 1](#F1){ref-type="fig"} illustrates the proportion of samples with a CNV, stratified by type of CNV, across cohorts.

We then stratified our dataset into samples containing CNVs covering gene coding (genic) regions and non-gene coding (intergenic) regions, as defined by RefSeq gene annotation coordinates available from the UCSC genome browser (<http://genome.ucsc.edu/>). The frequency of samples with deletion CNVs in gene coding regions was significantly increased in cases when compared to screened controls and WTCCC2 controls (p=4.2×10^−5^, OR 1.78 (95% CI 1.35 - 2.35) and p=7.2×10^−6^, OR 1.27 (95% CI 1.14 - 1.41) respectively). We further divided the samples with gene coding deletion CNVs into those with deletions interrupting exons and those with only intronic deletions. We found an increased frequency of cases with an exonic deletion CNV when compared to screened controls and WTCCC2 controls (p=1.70×10^−5^, OR 1.87 (95% CI 1.40 - 2.49) and p=1.04×10^−5^, OR 1.27 (95% CI 1.14 - 1.41) respectively). Intronic deletions were not associated (p=1.00, OR 1.00 (95% CI 0.38 - 2.60) and p=0.58, OR 0.91 (95% CI 0.66 - 1.24) respectively) however low numbers of samples with only intronic CNVs reduced our power to detect an effect. [Table 2](#T2){ref-type="table"} details results from this analysis and [Fig. 2](#F2){ref-type="fig"} illustrates the frequency of samples with exonic and intronic deletions, across cohorts. [Tables S1a](#SD1){ref-type="supplementary-material"} and [S1b in the supplementary information](#SD1){ref-type="supplementary-material"} detail all results for all regions, whilst [Fig S1a](#SD1){ref-type="supplementary-material"} contrasts the results for deletion CNVs shown in [Fig 2](#F2){ref-type="fig"} with the results for duplication CNVs. Further details on absolute numbers of CNVs, number of CNVs per sample, and mean and median CNV size can be found in [table S1k in the supplementary information](#SD1){ref-type="supplementary-material"}. Within an analysis for CNVs that occur only once in the dataset (singleton CNVs) we found a broadly similar enrichment within our cases when compared to the WTCCC2 control cohort (1 sided empirical p value = 0.0054). Further details of this analysis can be found in the [supplementary information](#SD1){ref-type="supplementary-material"}.

Analyses such as ours can be affected by differences in sample quality between groups, and also by population stratification. We attempted to account for this by performing analyses, post hoc, excluding the worst performing samples across our data set and restricted to a UK-only sample set. The association between deletion CNVs occurring across the whole genome, gene coding regions and exons remains significant in both analyses. Full details of these analyses are contained in pages 6-15 the [supplementary information](#SD1){ref-type="supplementary-material"}.

Given the differences indicated in [Figs 1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"} between the screened control cohort and the WTCCC2 control cohort we further analysed these two cohorts for significant differences, again stratifying by type of CNV made over A) genic and intergenic areas and B) exonic and intronic areas. There were no significant differences for the frequency of samples with CNVs throughout the genome between screened controls and WTCCC2 controls, although there was a trend for deletion CNVs (p=0.096, OR 1.22 (95% CI 0.97 - 1.54)). However, in the analysis stratified into genic/intergenic and exonic/intronic CNVs, significantly more deletion CNVs were seen in the WTCCC2 group than the screened control group in genic regions and exons (p=0.016, OR 1.40 (95% CI 1.06 - 1.84); p=0.0074, OR 1.47 (95% CI 1.11 - 1.95) respectively) but not in intergenic and intronic regions (p=0.79, OR 1.04 (95% CI 0.78 - 1.39) and p=1.00, OR 1.06 (95% CI 0.52 - 2.15) respectively. Again, low numbers of samples with only intronic CNVs reduced our power to detect an effect. No significant differences were seen in duplication CNV frequency. Results are presented in [table S1g in the online supplementary information](#SD1){ref-type="supplementary-material"}.

The WTCCC2 cohort is comprised of the 1958 British birth cohort and the national blood service cohort. As these represent samples drawn from different populations we performed an additional analysis comparing the frequency of samples with CNVs between these two subsets. More detail on this, details on stratification of our results by gender, and other information can be found in pages 18-22 of the [supplementary information](#SD1){ref-type="supplementary-material"}.

CNVs in various regions of the genome have previously been associated with psychiatric disorders such as schizophrenia ([@R26]). We performed an analysis across regions previously implicated in schizophrenia and a more detailed analysis of regions 1q21.1, 15q13.3 and 22q11.2 ([@R13], [@R14], [@R16]). We found that our cases were significantly enriched with CNVs in regions previously implicated in schizophrenia when compared to screened controls and when both deletions and duplications were considered together (p=0.0190, OR=3.21 (95%CI 1.07 - 9.68)). However no significant difference was observed when cases were compared to the WTCCC2 controls. We observed no significant differences in CNV frequency in the 1q21.1 region. We saw a nominally reduced frequency of cases with deletion or duplication CNVs in 15q13.3 compared to the national blood service subset of the WTCCC2 sample (p=0.044). We saw a nominally increased frequency of samples with deletion CNVs in 22q11.2 in our case sample when compared to the national blood service subset of the WTCCC2 control sample (p=0.045). Full details, including tables of frequencies for all regions and UCSC browser illustrations and individual CNV plots for regions 1q21.1, 15q13.3 and 22q11.2, can be found in pages 25-33 of the [supplementary information](#SD1){ref-type="supplementary-material"}.

DISCUSSION {#S9}
==========

This is the largest analysis of CNVs in recurrent depression performed to date. The results of our analysis suggest that rare deletion CNVs over 100Kb in size are significantly enriched in cases of recurrent depression. Furthermore, genic and exonic deletion CNVs show the greatest enrichment in our sample. We see a continuum of increasing deletion CNV frequency throughout our cohorts with the lowest frequency in screened controls, raised in unscreened controls and highest in cases. The only other study of CNVs in depressive disorder thus far focussed on individual variants rather than results from across the genome ([@R27]).

There is some weight to the hypothesis that cases of recurrent depression will be associated with CNVs. Other studies have found that deletion CNVs, and to a lesser extent duplication CNVs, are also associated with psychiatric disorders such as autism, schizophrenia and ADHD (see, for example ([@R11], [@R12], [@R15])). Furthermore, other research suggests that similar CNVs can predispose to a variety of neurological and psychiatric disorders ([@R10]). Other studies of CNVs in affective disorders have concentrated on bipolar disorder ([@R28], [@R29]). These studies do not find an association of CNVs with cases. Recurrent depression and bipolar disorder are overlapping but distinct disorders, so both results may be correct. In general the literature on CNVs in psychiatric disorders (especially autism and schizophrenia) supports the involvement of CNVs in specific areas of the genome, although the absolute numbers at each locus are low, and large sample sizes are needed to provide statistically significant evidence of association. Within [table S2a in the supplementary information](#SD1){ref-type="supplementary-material"} we present counts of CNVs in areas of the genome previously associated with schizophrenia. Whilst we find a significant difference when the total number of cases with CNVs in these areas is compared with the total number of screened controls with CNVs in these areas, no comparisons within individual areas are significant. However some areas warrant further research. For example, we see two and three cases respectively with the microdeletion and microduplication of 16p11.2 that has previously been associated with autism and schizophrenia respectively ([@R30], [@R31]). 2 out of 3 cases with the 16p11.2 duplication, but neither of the cases with the deletion, also had mood congruent psychotic symptoms. One case has the large 22q11.2 microdeletion associated with numerous clinical syndromes (as well as schizophrenia) ([@R32]). Exonic deletions in neurexin 1 have also been suggested to play a role in schizophrenia ([@R33], [@R34]). We see two cases with microdeletions affecting neurexin 1 in our cohort and 1 case with a deletion immediately downstream of the gene. 4 WTCCC2 controls have neurexin 1 deletions, and a further 2 have deletions immediately downstream of the gene. No screened controls have deletions of neurexin 1 within or downstream of the gene. Our data provides evidence for the presence of specific CNVs in some regions of the genome previously implicated in other psychiatric disorders in a minority of our cases.

In 1967 Gottesman and Shields commented that psychiatric disorders may represent the extremes of more general continuums of normal psychosocial functioning ([@R35]). They highlighted that this implied that the genetic aetiology of psychiatric disorders was likely to be highly complex. Modern research in psychiatric genetics indicates that this model may be applicable, and its renaissance is gathering momentum ([@R25], [@R36]). Perhaps those with a low number of deleterious CNVs, particularly deletions, are more likely to undergo development in a manner that fosters emotionally and cognitively adaptive behaviours associated with higher resilience to developing psychiatric disorders, such as recurrent depression. Such a theory may be applicable to other complex disorders in medicine, however it does suggest that the genetic aetiology of complex diseases will involve multiple genes, each with multiple biological effects, each subject to gene-gene interactions, and the entire milieu subject to environmental modification over the lifespan of the organism. Particular patterns of genetic variation and environmental interaction may be more strongly associated with complex disease than specific genes per se.

We performed a logistic regression analysis on our data (details in methods and [supplementary information](#SD1){ref-type="supplementary-material"}) which indicated that 0.87% (pseudo R^2^, Nagelkerke method, [table S3g in the supplementary information](#SD1){ref-type="supplementary-material"}) of the variance between RDD cases and screened controls is explained by our results. Although not explaining a large proportion, this is nonetheless a significant finding in a study of the genetic architecture of a complex disorder and underlines the genetic complexity of disorders such as recurrent depression. Only a limited number of large CNV events can be reliably detected using microarrays such as the Illumina Beadarray used in our experiment, and what we observe may extend to rare variants in general. In the near future more detailed studies, such as those involving large scale whole genome sequencing efforts, may uncover more rare variants than are currently detectable. This information will then allow us to make a better assessment of the role of rare variants in recurrent depression and psychiatric disorders in general.

Recurrent depression represents an increasingly prominent health problem, especially in developed countries. It conspicuously lacks any clinically useful biomarkers to guide diagnosis or treatment, which often proceeds on a trial-and-error basis and frequently does not lead to sustained remission. Elucidating the genetic architecture of diseases like recurrent depression has the potential to, in collaboration with other avenues of research, inform both diagnosis and treatment and our results thus represent a significant step towards identifying the biological underpinnings of a complex and hitherto genetically obscure psychiatric disorder.
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###### Frequency of samples with CNVs stratified by type, in screened controls, WTCCC2 controls and cases.

  -----------------------------------------------------------------------------------------------------
                                                     Screened Controls\   WTCCC2 Controls\   Cases\
                                                     (N=348)              (N=4828)           (N=2723)
  -------------------------------------------------- -------------------- ------------------ ----------
  **No. samples with a deletion**                    110\                 1740\              1123\
                                                     31.6%                36.0%              41.2%

  **No. samples with a duplication**                 132\                 1823\              1047\
                                                     37.9%                37.8%              38.5%

  **No. samples with a deletion or a duplication**   198\                 2932\              1725\
                                                     56.9%                60.7%              63.3%
  -----------------------------------------------------------------------------------------------------

###### Frequency of samples with gene coding deletion CNVs stratified into exonic, intronic, genic and intergenic regions, in screened controls, WTCCC2 controls and cases.

  ---------------------------------------------------------------------------------------------------------------------------------
                                                                                 Screened Controls\   WTCCC2 Controls\   Cases\
                                                                                 (N=348)              (N=4828)           (N=2723)
  ------------------------------------------------------------------------------ -------------------- ------------------ ----------
  **No. samples with an exonic deletion**[\*](#TFN1){ref-type="table-fn"}        61\                  1150\              774\
                                                                                 17.5%                23.8%              28.4%

  **No. samples with an intronic deletion** [\*\*](#TFN2){ref-type="table-fn"}   8\                   117\               60\
                                                                                 2.3%                 2.4%               2.2%

  **No. samples with a genic deletion**                                          67\                  1208\              811\
                                                                                 19.2%                25.0%              29.8%

  **No. samples with an intergenic deletion**                                    59\                  846\               523\
                                                                                 17.0%                17.5%              19.2%
  ---------------------------------------------------------------------------------------------------------------------------------

Refers to samples with deletions with any exonic coverage

Refers to samples with deletions with only intronic coverage
